Investing
The company's platform predicts how people in a clinical trial will respond to treatment.
The funds will be used to expand the company's workforce and accelerate development of its AI-powered patient engagement platform, Assort OS.
The company will use the funds to scale nationally, broaden partnerships with payers and health systems, and expand into new neurological condition areas.
The company makes upright radiation therapy systems using a fixed beam with slow patient rotation instead of a gantry.
Telehealth company Caregility, hybrid cancer care company Daymark Health and virtual care company AmplifyMD also garnered funding.
The company will use the funds to expand Dreem Health, scale nationwide and advance its FDA-cleared sleep apnea technology.
The Series D funding brings the company’s total raise to $275 million and its valuation to more than $1 billion.
The company anticipates doubling its revenue this year reaching $1 billion in sales.
The company stated Capital Rx will still operate as its pharmacy benefits manager brand under Judi Health.
The funds will be used to expand its customer base and invest in AI innovation.